The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical and translational investigation of pan-HDAC inhibition in advanced urothelial carcinoma (UC).
 
Sumati Gupta
Stock and Other Ownership Interests - Salarius Pharmaceuticals (I)
Consulting or Advisory Role - Keryx (I)
Research Funding - Hydrocephalus Clinical Research Network (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Viralytics (Inst)
Travel, Accommodations, Expenses - Keryx (I)
 
Daniel Joseph Albertson
No Relationships to Disclose
 
Timothy Parnell
No Relationships to Disclose
 
Brian Dalley
No Relationships to Disclose
 
John O Shea
No Relationships to Disclose
 
Alexis Weston
No Relationships to Disclose
 
Andrew Butterfield
No Relationships to Disclose
 
Lisa M. Pappas
No Relationships to Disclose
 
Joshua David Schiffman
Stock and Other Ownership Interests - ItRunsInMyFamily.com; PEEL Therapeutics
Honoraria - Affymetrix
Consulting or Advisory Role - N-of-One; Omicia
 
Sunil Sharma
Stock and Other Ownership Interests - Beta Cat Pharmaceuticals; ConverGene; Salarius Pharmaceuticals; Stingray Therapeutics
Honoraria - Blend Therapeutics; Foundation Medicine; Foundation Medicine; Guardant Health; Novartis; Novartis; Novartis
Research Funding - Amgen (Inst); Bayer (Inst); Blueprint Medicines (Inst); Celgene (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Johnson & Johnson (Inst); Labceutics (Inst); Labceutics (Inst); MedImmune (Inst); Merck (Inst); Merrimack (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Onyx (Inst); Plexxikon (Inst); Sanofi (Inst); Spectrum Pharmaceuticals (Inst); XuanZhu (Inst)
Patents, Royalties, Other Intellectual Property - Patent Pending: “Substituted N-Phenylpyrimidin-2-Amine Analogs as Inhibitors of the AXL Kinase”. U.S. Patent No. WO 2012135800 A1 20121004. Washington, D.C.:U.S. Patent and Trademark Office.; Patent: “Substituted 3-(IH-Benzo[D]Imidazol-2-YL)-IH-Indazole Analogs as Inhibitors of the PDKI Kinase”. U.S. Patent No. WO 2012135799 A1 20121004. Washington, D.C.:U.S. Patent and Trademark Office.; Patent: “Substituted N-(3-(Pyrimidin-4-YL)Phenyl)Acrylamide Analogs as Tyrosine Receptor Kinase BTK Inhibitors”. U.S. Patent No. US 8,703,767 B2. Washington, D.C.:U.S. Patent and Trademark Office.
Travel, Accommodations, Expenses - Guardant Health
 
Neeraj Agarwal
Research Funding - amgen (Inst); Bayer (Inst); BN ImmunoTherapeutics (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); ImClone Systems (Inst); Medivation (Inst); Novartis (Inst); Pfizer (Inst); Rexahn Pharmaceuticals (Inst); Takeda (Inst); TRACON Pharma (Inst)